DoD (Army contracting): ~$12.5B for 10M courses of an oral antiviral (PF-07321332) — a contract with Pfizer (USAspending)
An Army contracting component awarded about $12.5B ($12,549,999,848) to Pfizer for 10 million courses of the oral protease inhibitor PF-07321332 (nirmatrelvir, the active component of Paxlovid). An example of the defense procurement system used for pandemic-response drug purchasing.
Contract key facts
- RecipientPfizer
- Contract value$12,549,999,848 (≈$12.55B)
- BranchArmy
- Awarding agencyDepartment of Defense
- Awarding sub-agencyDepartment of the Army
- Award typeDEFINITIVE CONTRACT
- Period of performance2021-11-17 〜 2023-03-31
- Contract ID (PIID)W58P0522C0001
Contract scope (original)
AWARD OF 10M TREATMENT COURSES OF ORAL PROTEASE INHIBITOR PF-07321332
Key points
- An Army contracting component procured 10M courses of an oral antiviral
- PF-07321332 = nirmatrelvir = the active component of Paxlovid
- Value ~$12.5B, period of performance November 2021–March 2023
- The defense procurement system used for pandemic-response drug buying
- Recipient: pharmaceutical leader Pfizer
- An oral medicine can be taken at home, which is why quantity is counted in treatment courses rather than doses.
1Procuring 10 million courses of an oral antiviral from Pfizer, about $12.5 billion
The Department of Defense, through an Army contracting component, awarded Pfizer Inc a contract for 10 million treatment courses of the oral protease inhibitor "PF-07321332," worth about $12.5 billion with performance from 17 November 2021 to 31 March 2023. PF-07321332 is the development code name for nirmatrelvir, the active component of the COVID-19 oral treatment "Paxlovid" (Paxlovid combines nirmatrelvir with ritonavir).
2What it means that the drug is oral
Unlike a medicine given by infusion or injection, an oral drug can be taken at home without a trip to a health-care facility. For a treatment meant to be started early after symptoms begin, that ease of delivery translates directly into ease of use. The fact that the quantity is counted in treatment courses — one full run of doses for one person — rather than in vials or doses reflects a procurement built around that use.
3Why the defense contracting machinery was used
4Being oral changes the shape of the procurement
Unlike a drug given by infusion or injection, an oral medicine can be taken at home without visiting a clinic. That difference shows up not only in reach but in how the quantity is counted.
For a therapeutic meant to be used early after onset, that ease of delivery tells. A scale of 10 million treatment courses shows a government making an enormous, effectively prepaid purchase from a single company under emergency conditions. PF-07321332 is the development code for nirmatrelvir, the active component of the oral COVID-19 therapeutic Paxlovid.
Why it matters
A concrete example of the DoD's contracting machinery used for pandemic-response drug purchasing. Useful for understanding emergency government procurement and the scale of public-private vaccine/therapeutic supply.
FAQ
What data is this?
What is PF-07321332?
Why would the "Army" buy a drug?
Sources (primary)
This article is an independent organization based on the U.S. official spending data below. Verify the exact, latest details with the official source.
- USAspending (award details)
- Contract ID (PIID):W58P0522C0001